S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
NASDAQ:XNCR

Xencor (XNCR) Stock Price, News & Analysis

$26.52
+0.65 (+2.51%)
(As of 02/27/2024 ET)
Today's Range
$25.92
$26.84
50-Day Range
$18.65
$26.52
52-Week Range
$16.49
$33.38
Volume
1.06 million shs
Average Volume
653,069 shs
Market Capitalization
$1.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.83

Xencor MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.2% Upside
$39.83 Price Target
Short Interest
Bearish
9.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.04mentions of Xencor in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$1.99 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.31) to ($3.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.60 out of 5 stars

Medical Sector

267th out of 944 stocks

Pharmaceutical Preparations Industry

113th out of 406 stocks


XNCR stock logo

About Xencor Stock (NASDAQ:XNCR)

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

XNCR Stock Price History

XNCR Stock News Headlines

Xencor: Q4 Earnings Snapshot
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Xencor earnings preview: what Wall Street is expecting
6XNCR : Earnings Preview: Xencor
Xencor (XNCR) to Release Earnings on Tuesday
Xencor (NASDAQ:XNCR) Stock Rating Upgraded by StockNews.com
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
KPTI Aug 2024 1.000 call
KPTI May 2024 2.000 put
Xencor (NASDAQ:XNCR) Trading 6% Higher
IONS Mar 2024 42.500 call
Xencor: Standing Out With XmAb Technology
Navigating 4 Analyst Ratings For Xencor
See More Headlines
Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
2/27/2024
Next Earnings (Confirmed)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XNCR
Employees
281
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.83
High Stock Price Target
$50.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+50.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-55,180,000.00
Pretax Margin
-82.23%

Debt

Sales & Book Value

Annual Sales
$164.58 million
Book Value
$12.14 per share

Miscellaneous

Free Float
57,850,000
Market Cap
$1.61 billion
Optionable
Optionable
Beta
0.70
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Bassil I. Dahiyat Ph.D. (Age 54)
    Co-Founder, CEO, President & Director
    Comp: $1.08M
  • Mr. John J. Kuch (Age 65)
    Senior VP & CFO
    Comp: $660.75k
  • Dr. John R. Desjarlais Ph.D. (Age 60)
    Executive VP of Research & Chief Scientific Officer
    Comp: $711.45k
  • Ms. Celia E. Eckert J.D. (Age 51)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $646.25k
  • Dr. Nancy Valente M.D. (Age 65)
    Executive VP & Chief Development Officer
    Comp: $28.16k
  • Mr. Charles Liles
    Associate Director and Head of Corporate Communications & Investor Relations
  • Ms. Jennifer Sandoz
    Vice President of Human Resources
  • Dr. Jeremy Grunstein Ph.D.
    Senior Vice President of Business Development
  • Mr. Kirk Rosemark RAC (Age 59)
    Senior Vice President of Regulatory Affairs & Quality Assurance
  • Mr. Eric P. Kowack
    Senior Vice President of Program Leadership & Alliance Management














XNCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Xencor stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings
or view top-rated stocks.

What is Xencor's stock price target for 2024?

6 brokerages have issued twelve-month price objectives for Xencor's stock. Their XNCR share price targets range from $32.00 to $50.00. On average, they expect the company's stock price to reach $39.83 in the next year. This suggests a possible upside of 50.2% from the stock's current price.
View analysts price targets for XNCR
or view top-rated stocks among Wall Street analysts.

How have XNCR shares performed in 2024?

Xencor's stock was trading at $21.23 at the start of the year. Since then, XNCR stock has increased by 24.9% and is now trading at $26.52.
View the best growth stocks for 2024 here
.

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our XNCR earnings forecast
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) posted its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.77) by $0.37. The biopharmaceutical company had revenue of $59.16 million for the quarter, compared to analyst estimates of $30.01 million. Xencor had a negative net margin of 81.94% and a negative trailing twelve-month return on equity of 17.26%. Xencor's revenue for the quarter was up 116.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.55) earnings per share.

What ETFs hold Xencor's stock?
What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

Who are Xencor's major shareholders?

Xencor's stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (14.62%), Vanguard Group Inc. (11.12%), Price T Rowe Associates Inc. MD (5.72%), Price T Rowe Associates Inc. MD (5.72%), Armistice Capital LLC (2.46%) and Dimensional Fund Advisors LP (2.10%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert, John J Kuch and John R Desjarlais.
View institutional ownership trends
.

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XNCR) was last updated on 2/28/2024 by MarketBeat.com Staff